



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 5/2/06

Signature:

Christine Grace
(Christine Grace)

Docket No.: YU-P01-021
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Chin et al.

Application No.: 09/840085

Confirmation No.: 2186

Filed: April 24, 2001

Art Unit: 1647

For: DNA AND PROTEIN BINDING
MINIATURE PROTEINS

Examiner: M. P. Allen

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue there from.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Copies of non-patent documents CA – CM1 are enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. YU-P01-021. A duplicate copy of this paper is enclosed.

Dated: May 2, 2006

Respectfully submitted,

By 

Z. Angela Guo

Registration No.: 54,144

ROPES & GRAY LLP


One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).		Complete if Known	
FEE TRANSMITTAL For FY 2006		Application Number	09/840085
		Filing Date	April 24, 2001
		First Named Inventor	Jason W.K. Chin
		Examiner Name	M. P. Allen
		Art Unit	1647
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Attorney Docket No.	YU-P01-021	
TOTAL AMOUNT OF PAYMENT	(\$) 180.00		

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____
☒ Deposit Account Deposit Account Number: 18-1945 Deposit Account Name: Ropes & Gray LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, **except for the filing fee**
☒ Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>
_____	_____	_____	_____	<u>Fee (\$)</u>
_____	_____	_____	_____	<u>Fee Paid (\$)</u>
<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	
_____	_____	_____	_____	
_____	_____	_____	_____	

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
_____	_____	_____	_____	_____
_____ - 100 = _____ / 50 _____ (round up to a whole number) x _____ = _____				

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)	
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement	180.00

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	54,144
Name (Print/Type)	Z. Angela Guo	Telephone	(617) 951-7546
		Date	May 2, 2006

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 5/2/06 Signature: Christine M. Grace (Christine M. Grace)



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/840085	
			Filing Date	April 24, 2001	
			First Named Inventor	Jason W.K. Chin	
			Art Unit	1647	
			Examiner Name	M.P. Allen	
Sheet	1	of	3	Attorney Docket Number	YU-P01-021

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Akamine, P., et al., "Dynamic Features of cAMP-dependent Protein Kinase Revealed by Apoenzyme Crystal Structure," J. Mol. Biol., 327:159-171 (2003).	
	CB	Bridges, A., "Chemical Inhibitors of Protein Kinases," Chem Rev., 101:2541-72 (2001).	
	CC	Cheng, H.C., et al., "A Potent Synthetic Peptide Inhibitor of the cAMP-dependent Protein Kinase," J. Biol. Chem., 261(3):989-992 (1986).	
	CD	Chin, J. W. and Schepartz, A., "Design and Evolution of a Miniature Bcl-2 Binding Protein", Agnew. Chem. Int. Ed., 20:3806-3809 (2001).	
	CE	Chin, J.W., and Schepartz, A., "Concerted Evolution of Structure and Function in a Miniature Protein," J. Am. Chem. Soc., 123:2929-2930 (2001).	
	CF	Cohen, P., "The Development and Therapeutic Potential of Protein Kinase Inhibitors," Current Opinion in Chemical Biology, 3:459-465 (1999).	
	CG	Du, K., et al., "Characterization of a CREB Gain-of-Function Mutant with Constitutive Transcriptional Activity In Vivo," Mol. Cell. Biol., 20:4320-4327 (2000).	
	CH	García-Echeverría, C., et al., "Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53," J. Med. Chem., 43:3205-3208 (2000).	
	CI	Glass, D., et al., "Protein Kinase Inhibitor-(6-22)-amide Peptide Analogs with Standard and Nonstandard Amino Acid Substitutions for Phenylalanine 10," J. Biol. Chem., 264:14579-14584 (1989).	
	CJ	Glass, D., et al., "Differential and Common Recognition of the Catalytic Sites of the cGMP-dependent and cAMP-dependent Protein Kinases by Inhibitory Peptides Derived from the Heat-stable Inhibitor Protein," J. Biol. Chem., 261:12166-12171 (1986).	
	CK	Glass, D., et al., "Primary Structural Determinants Essential for Potent Inhibition of cAMP-dependent Protein Kinase by Inhibitory Peptides Corresponding to the Active Portion of the Heat-stable Inhibitor Protein," J. Biol. Chem., 264:8802-8810 (1989).	
	CL	Glover, I., et al., "Conformational Flexibility in a Small Globular Hormone: X-Ray Analysis of Avian Pancreatic Polypeptide at 0.98-Å Resolution," Biopolymers, 22:293-304 (1983).	
	CM	Glover, I., et al., "Crystal Structure of the Heterodimeric bZIP Transcription Factor c-Fos-c-Jun Bound to DNA," Nature, 373:257-261 (1995).	
	CN	Gonzalez, G., et al., "Cyclic AMP Stimulates Somatostatin Gene Transcription by	



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/840085
				Filing Date	April 24, 2001
				First Named Inventor	Jason W.K. Chin
				Art Unit	1631
				Examiner Name	C. Mahatan
Sheet	2	of	2	Attorney Docket Number	YU-P01-021

		Phosphorylation of CREB at Serine 133," Cell, 59:675-680 (1989).	
CO		Hashimoto, Y., et al., "Potent and Preferential Inhibition of Ca ²⁺ / Calmodulin-Dependent Protein Kinase II by K252a and its Derivative, KT5926," Biochem. Biophys. Res. Comm., 181:423-429 (1991).	
CP		Johannessen, M., et al., "Synergistic Activation of CREB-mediated Transcription by Forskolin and Phorbol Ester Requires PKC and Depends on the Glutamine-rich Q2 Transactivation Domain," Cell. Signal., 16:1187-1199 (2004).	
CQ		Johnson, D., et al., "Dynamics of cAMP-Dependent Protein Kinase," Chem. Rev., 101:2243-2270 (2001).	
CR		Kase, H., et al., "K-252 Compounds, Novel and Potent Inhibitors of Protein Kinase C and Cyclic Nucleotide-Dependent Protein Kinases," Biochem. Biophys. Res. Commun., 142:436-440 (1987).	
CS		Kase, H., et al., "K-252a, A Potent Inhibitor of Protein Kinase C from Microbial Origin," J. Antibiot., 39:1059-1065 (1986).	
CT		Kettleborough, C., et al., "Isolation of Tumor Cell-specific Single-chain Fv from Immunized Mice Using Phage-antibody Libraries and the Re-construction of Whole Antibodies from these Antibody Fragments," Eur. J. Immunol., 24:952-958 (1994).	
CU		Knighton, D., et al., "Structure of a Peptide Inhibitor Bound to the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase," Science, 253:414-420 (1991).	
CV		Liljas, A., et al., "Crystal Structure of Human Carbonic Anhydrase C," Nat. New Biol., 235:131-137 (1972).	
CW		Meador, W., et al., "Target Enzyme Recognition by Calmodulin: 2.4 Å Structure of a Calmodulin-Peptide Complex," Science, 257:1251-1255 (1992).	
CX		Mestas, S. and Lumb, K., "Electrostatic Contribution of Phosphorylation to the Stability of the CREB-CBP Activator-Coactivator Complex," Nat. Struct. Biol., 6:613-614 (1999).	
CY		Miller, W. T., "Double Trouble," Nat. Struct. Biol., 8:16-18 (2001).	
CZ		Munson, P., et al., "An Exact Correction to the 'Cheng-Prusoff' Correction," J. Recept. Res., 8:533-546 (1988).	
CA1		Parker, D., et al., "Role of Secondary Structure in Discrimination between Constitutive and Inducible Activators," Mol. Cell Biol., 19:5601-5607 (1999).	
CB1		Parker, D., et al., "Analysis of an Activator: Coactivator Complex Reveals an Essential Role for Secondary Structure in Transcriptional Activation," Mol. Cell., 2:353-359 (1998).	
CC1		Prade, L., et al., "Staurosporine-induced Conformational Changes of cAMP-dependent Protein Kinase Catalytic Subunit Explain Inhibitory Potential," Structure, 5:1627-1637 (1997).	
CD1		Rutledge, S. et al., "Molecular Recognition of Protein Surfaces: High Affinity Ligands for the CBP KIX Domain," J. Am. Chem. Soc., 125:14336-14347 (2003).	
CE1		Scapin, G., "Structural Biology in Drug Design: Selective Protein Kinase Inhibitors," Drug Discov. Today, 7:601-611 (2002).	
CF1		Tapley, P., et al., "K252a is a Selective Inhibitor of the Tyrosine Protein Kinase Activity of the trk Family of Oncogenes and Neurotrophin Receptors," Oncogene, 7:371-381 (1992).	
CG1		Weiss, M., et al., "Folding Transition in the DNA-binding Domain of GCN4 on Specific Binding to DNA," Nature, 347:575-578 (1990).	
CH1		Whitehouse, S., et al., "Studies on the Kinetic Mechanism of the Catalytic Subunit of the cAMP-dependent Protein Kinase," J. Biol. Chem., 258:3693-3701 (1983).	
CI1		Wu, X., et al., "The p53-mdm-2 Autoregulatory Feedback Loop," J. Genes Dev., 7:1126-1132 (1993).	
CJ1		Zhang, Z., et al., "Selection and Application of Peptide-binding Peptides," Nat. Biotech., 18:71-74 (2000).	
CK1		Zheng, J., et al., "A Refined Crystal Structure of the Catalytic Subunit of cAMP-Dependent Protein Kinase Complexed with MnATP and a Peptide Inhibitor," Acta Cryst., D49:362-365 (1993).	



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/840085
				Filing Date	April 24, 2001
				First Named Inventor	Jason W.K. Chin
				Art Unit	1631
				Examiner Name	C. Mahatan
Sheet	3	of	2	Attorney Docket Number	YU-P01-021

	CL1	Zimmermann, J., et al., "Potent and Selective Inhibitors of the ABL-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives," Bioorg. Med. Chem. Lett., 7:187-192 (1997).	
	CM1	Zor, T., et al., "Roles of Phosphorylation and Helix Propensity in the Binding of the KIX Domain of CREB-binding Protein by Constitutive (c-Myb) and Inducible (CREB) Activators," J. Biol. Chem., 277:42241-42248 (2002).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.